Follow us:

Latest News

WINNER: National Sleep Foundation – Sleep Tech Award

Life Science Industry Awards

Kate Willis appointment

CEO Appointed Visiting Scholar at UC San Diego

CPO Joins the Shott Scale Up Accelerator Cohort

Modius Sleep at SLEEP 2025

This year, Neurovalens is excited to be part of SLEEP 2025, where we will showcase Modius Sleep, a revolutionary, FDA-cleared, non-invasive device designed to improve sleep quality for patients suffering from chronic insomnia. Join us for live demonstrations, explore groundbreaking research, and connect with our expert team to learn how Modius Sleep is setting a new standard in sleep care.

Celebrating Success at the BVCA Vision 2025 Awards

Neurovalens earned recognition in the Early Stage category at the awards. This year, the awards took place at the iconic Merchant Hotel in Belfast on Thursday, May 22, 2010. Neurovalens Chief Technology Officer Chris McCabe and Chief Regulatory Officer Sinead Watson attended the awards.

Modius Sleep Now Available to U.S. Veterans Through VA Program

At Neurovalens, we are dedicated to improving lives through cutting-edge neurotechnology. We are thrilled to announce that Modius Sleep, our innovative, noninvasive treatment for chronic insomnia, is now available to U.S. veterans through the Department of Veterans Affairs (VA) program. This marks a significant milestone in our mission to provide drug-free solutions for better sleep and overall well-being.

Sleep Reimagined: Modius Sleep

In a recent webinar, Dr. Audrey Wells, founder of Super Sleep MD, and Dr. Jason McKeown, CEO of Neurovalens, explored innovative approaches to improving sleep quality without the reliance on medication. The discussion centered around Modius Sleep, a revolutionary, FDA-cleared medical device designed to enhance sleep through non-invasive neurostimulation.

Modius Sleep Featured as a Top Sleep Gadget for 2025 by CBS TechSesh

TechSesh, a leading tech and lifestyle publication, recently published an article titled “Better Sleep Into the New Year: 3 Gadgets to Help You Rest Easier”. The piece showcases the latest innovations designed to help improve sleep quality, and we’re proud to see Modius Sleep recognized among the top recommendations.

Neurovalens Win National Sleep Foundation’s 2024 SleepTech® Award

The National Sleep Foundation (NSF) Neurovalens as winners of the 2024 SleepTech® Award. NSF’s SleepTech Award recognizes the year’s most innovative efforts in advancing sleep technology and is a feature of NSF’s ongoing work to encourage and celebrate efforts when sleep science and insight are rapidly incorporated into accessible health products and services.

Our Type 2 Diabetes Clinical Trial Has Successfully Concluded!

The study tested the safety and effectiveness of a non-drug, non-invasive neurostimulation wearable device designed to help adults with Type 2 Diabetes improve their blood sugar control.

Neurovalens shines at the 2024 Life Science Industry Awards

We are delighted to have been awarded the Small Life Science Company of the Year at the 2024 Life Science Industry Awards, held in Dublin on the 27th of June. The event recognised the most innovative individuals and companies leading excellence in Ireland's life sciences sector.

Neurovalens Appoints Kate Willis as Vice President of Commercialization

Kate Willis has been appointed as the Vice President of Commercialization, where she will oversee the sales of Neurovalens' prescribed medical devices in the US and work towards securing reimbursement approvals from private healthcare insurance providers.

We're Hiring: Logistics Associate

Neurovalens is looking for an enthusiastic Logistics Associate to join our passionate and hard working team. This an exciting time for an ambitious individual to consider a career at Neurovalens.

Neurovalens CEO Appointed Visiting Scholar at UC San Diego

Neurovalens CEO, Dr. Jason McKeown has been appointed as a Visiting Scholar at the prestigious University of California, San Diego (UCSD), joining the Department of Psychiatry. This appointment marks a journey that began nearly a decade ago when Jason first collaborated with UCSD.

Neurovalens receives FDA clearance for medical device to treat anxiety

Modius Stress becomes company’s second product cleared for use in US. Neurovalens, a global leader in non-invasive neuro-technology, has received medical device clearance from the US Food & Drug Administration (FDA) to treat anxiety with its Modius Stress device

Celebrating Success: Neurovalens Triumphs at Digital DNA Awards 2024

Neurovalens were delighted to be awarded two recognitions at the 2024 Digital DNA awards in Belfast’s ICC, Waterfront on Thursday, March 21st. Small Tech Company of the Year and Highly Commended in the Tech For Good category.

Iain Hendrick (CPO) Joins the Shott Scale Up Accelerator Cohort for 2024

Building a high-performance team requires high performance leadership. Our Chief Project Officer, Iain Hendrick, will be spending the next 12 months on the Shott Scale Up Accelerator program with the Royal Academy of Engineering.

UK Innovation at Arab Health

Neurovalens were delighted to take our FDA Cleared Modius Sleep technology to Arab Health 2024, a Global Healthcare Medical Expo in Dubai from 29th January to 1st February 2024.

ISO 13485 Certified Medical Device Company

Neurovalens are an ISO 13485 certified medical device company. This is an international standard that sets out regulatory requirements for medical device quality management systems.

Neurovalens at 10 Downing Street

Our CEO, Jason McKeown was invited back to 10 Downing Street today to discuss our recently FDA cleared treatment for chronic insomnia.

Medica 2023

CPO Iain Hendrick and Software QA Manager Steven George attended Medica 2023 in Düsseldorf, Germany to showcase the newly FDA cleared Modius Sleep headset.

Neurovalens receives FDA clearance for medical device to treat insomnia

Neurovalens, a global leader in non-invasive neuro-technology, has received medical device clearance from the US Food & Drug Administration (FDA) to treat chronic insomnia with its Modius Sleep device.

Modius Spero - A non-invasive, drug-free technology being trialled as a potential treatment for PTSD

Neurovalens is studying the efficacy of a non-invasive electrical vestibular nerve stimulation (VeNS) device, the Modius Spero device, as a method of treating Post-Traumatic Stress Disorder (PTSD).

Featured in

Join the Neurovalens Mailing List

Keep up to date with our latest products, research and company news.

Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges.

Our medical device technology offers unparalleled transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus, allowing for alterations in autonomic function, circadian regulation and Neuro-metabolic influence.

Useful Links

Information